Congress May Overturn Some Agency Rules, & More from CRS
“With a change of presidential administrations taking place in January, some in Congress are paying renewed attention to a parliamentary mechanism that might enable the new Congress and the new President to overturn agency final rules of the Obama Administration issued after late-May 2016,” a newly updated brief from the Congressional Research Service explains.
“The inauguration of Republican Donald J. Trump as President in 2017 may present a finite window during which the [congressional] disapproval mechanism might be used more successfully.” See Agency Final Rules Submitted After May 30, 2016, May Be Subject to Disapproval in 2017 Under the Congressional Review Act, CRS Insight, updated November 9, 2016.
Other new and updated reports from the Congressional Research Service include the following.
Legislative Actions to Repeal, Defund, or Delay the Affordable Care Act, updated November 10, 2016
“Regulatory Relief” for Banking: Selected Legislation in the 114th Congress, updated November 10, 2016
Retirement Benefits for Members of Congress, updated November 10, 2016
Staff Tenure in Selected Positions in Senate Committees, 2006-2016, November 9, 2016
Staff Tenure in Selected Positions in Senators’ Offices, 2006-2016, November 9, 2016
Staff Tenure in Selected Positions in House Committees, 2006-2016, November 9, 2016
Staff Tenure in Selected Positions in House Member Offices, 2006-2016, November 9, 2016
U.S. Trade with Free Trade Agreement (FTA) Partners, updated November 9, 2016
China Issues Decision on Hong Kong Legislative Council Controversy, CRS Insight, November 9, 2016
Navy Force Structure: A Bigger Fleet? Background and Issues for Congress, updated November 9, 2016
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.
Called today to speak on behalf of U.S. science and technology, Dr. Jedidah Isler, astrophysicist, educator, strategist, policy-maker, and science communicator, will provide constructive, nonpartisan feedback to the House Committee’s hearing “American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership.”
“Federal data and access to it is not a partisan issue. It is a people issue. Our country cannot achieve greatness without access to the data that measure what we value, who we are, and where we’re heading.”
The United States’ biosecurity governance system is structurally incapable of detecting and responding to certain classes of threats. U.S. biosecurity tools have not kept pace with technological advancements or a changing threat landscape.